[1] |
Zhang XJ, Chen JJ, Liu JB. The genetic concept of vitiligo[J]. J Dermatol Sci, 2005, 39(3): 137⁃146. DOI: 10.1016/j.jdermsci.2005.06.004.
|
[2] |
Kemp EH, Waterman EA, Weetman AP. Autoimmune aspects of vitiligo[J]. Autoimmunity, 2001, 34(1): 65⁃77.
|
[3] |
Hegedus L, Heildenheim M, Gervil M, et al. High frequency of thyroid dysfunction in patients with vitiligo[J]. Acta Derm Venereol, 1994, 74(2): 120⁃123.
|
[4] |
van den Boorn JG, Konijnenberg D, Dellemijn TA, et al. Autoimmune destruction of skin melanocytes by perilesional T cells from vitiligo patients[J]. J Invest Dermatol, 2009, 129(9): 2220⁃2232. DOI: 10.1038/jid.2009.32.
|
[5] |
Dwivedi M, Laddha NC, Arora P, et al. Decreased regulatory T⁃cells and CD4+/CD8+ ratio correlate with disease onset and progression in patients with generalized vitiligo[J]. Pigment Cell Melanoma Res, 2013, 26(4): 586⁃591. DOI: 10.1111/pcmr.12105.
|
[6] |
Lin M, Zhang BX, Shen N, et al. Regulatory T cells from active non⁃segmental vitiligo exhibit lower suppressive ability on CD8+CLA+ T cells[J]. Eur J Dermatol, 2014, 24(6): 676⁃682. DOI: 10.1684/ejd.2014.2436.
|
[7] |
Kotobuki Y, Tanemura A, Yang L, et al. Dysregulation of melanocyte function by Th17⁃related cytokines: significance of Th17 cell infiltration in autoimmune vitiligo vulgaris[J]. Pigment Cell Melanoma Res, 2012, 25(2): 219⁃230. DOI: 10.1111/j.1755⁃148X.2011.00945.x.
|
[8] |
Zhou L, Shi YL, Li K, et al. Increased circulating Th17 cells and elevated serum levels of TGF⁃beta and IL⁃21 are correlated with human non⁃segmental vitiligo development[J]. Pigment Cell Melanoma Res, 2015, 28(3): 324⁃329. DOI: 10.1111/pcmr.12355.
|
[9] |
Chatterjee S, Eby JM, Al⁃Khami AA, et al. A quantitative increase in regulatory T cells controls development of vitiligo[J]. J Invest Dermatol, 2014, 134(5): 1285⁃1294. DOI: 10.1038/jid.2013.540.
|
[10] |
Rashighi M, Agarwal P, Richmond JM, et al. CXCL10 is critical for the progression and maintenance of depigmentation in a mouse model of vitiligo[J]. Sci Transl Med, 2014, 6(223): 223ra23. DOI: 10.1126/scitranslmed.3007811.
|
[11] |
Mosenson JA, Flood K, Klarquist J, et al. Preferential secretion of inducible HSP70 by vitiligo melanocytes under stress[J]. Pigment Cell Melanoma Res, 2014, 27(2): 209⁃220. DOI: 10.1111/pcmr.12208.
|
[12] |
Mosenson JA, Zloza A, Nieland JD, et al. Mutant HSP70 reverses autoimmune depigmentation in vitiligo[J]. Sci Transl Med, 2013, 5(174): 174ra28. DOI: 10.1126/scitranslmed.3005127.
|
[13] |
Richmond JM, Frisoli ML, Harris JE. Innate immune mechanisms in vitiligo: danger from within[J]. Curr Opin Immunol, 2013, 25(6): 676⁃682. DOI: 10.1016/j.coi.2013.10.010.
|
[14] |
Yu R, Broady R, Huang Y, et al. Transcriptome analysis reveals markers of aberrantly activated innate immunity in vitiligolesional and non⁃lesional skin[J]. PLoS One, 2012, 7(12): e51040. DOI: 10.1371/journal.pone.0051040.
|
[15] |
Marie J, Kovacs D, Pain C, et al. Inflammasome activation and vitiligo/nonsegmental vitiligo progression[J]. Br J Dermatol, 2014, 170(4): 816⁃823. DOI: 10.1111/bjd.12691.
|
[16] |
Bertolotti A, Boniface K, Vergier B, et al. Type I interferon signature in the initiation of the immune response in vitiligo[J]. Pigment Cell Melanoma Res, 2014, 27(3): 398⁃407. DOI: 10.1111/pcmr.12219.
|
[17] |
Shi Q, Zhang W, Guo S, et al. Oxidative stress⁃induced overex⁃pression of miR⁃25: the mechanism underlying the degeneration of melanocytes in vitiligo[J]. Cell Death Differ, 2016, 23(3): 496⁃508. DOI: 10.1038/cdd.2015.117.
|
[18] |
Al⁃Shobaili HA, Rasheed Z. Oxidized tyrosinase: a possible antigenic stimulus for non⁃segmental vitiligo autoantibodies[J]. J DermatolSci, 2015, 79(3): 203⁃213. DOI: 10.1016/j.jdermsci.2015.06.009.
|
[19] |
Laddha NC, Dwivedi M, Mansuri MS, et al. Role of oxidative stress and autoimmunity in onset and progression of vitiligo[J]. Exp Dermatol, 2014, 23(5): 352⁃353. DOI: 10.1111/exd.12372.
|
[20] |
Wang X, Du J, Wang T, et al. Prevalence and clinical profile of vitiligo in China: a community⁃based study in six cities[J]. ActaDermVenereol, 2013, 93(1): 62⁃65. DOI: 10.2340/00015555⁃1397.
|
[21] |
Spritz RA. Modern vitiligo genetics sheds new light on an ancient disease[J]. J Dermatol, 2013, 40(5): 310⁃318. DOI: 10.1111/1346⁃8138.12147.
|
[22] |
Quan C, Ren YQ, Xiang LH, et al. Genome⁃wide association study for vitiligo identifies susceptibility loci at 6q27 and the MHC[J]. Nat Genet, 2010, 42(7): 614⁃618. DOI: 10.1038/ng.603.
|
[23] |
Tang XF, Zhang Z, Hu DY, et al. Association analyses identify three susceptibility Loci for vitiligo in the Chinese hanpopulation[J]. J Invest Dermatol, 2013, 133(2): 403⁃410. DOI: 10.1038/jid.2012.320.
|
[24] |
Huang Y, Yi X, Jian Z, et al. A single⁃nucleotide polymorphism of miR⁃196a⁃2 and vitiligo: an association study and functional analysis in a Han Chinese population[J]. Pigment Cell Melanoma Res, 2013, 26(3): 338⁃347. DOI: 10.1111/pcmr.12081.
|
[25] |
Webb KC, Tung R, Winterfield LS, et al. Tumour necrosis factor⁃α inhibition can stabilize disease in progressive vitiligo[J]. Br J Dermatol, 2015, 173(3): 641⁃650. DOI: 10.1111/bjd.14016.
|
[26] |
Camara⁃Lemarroy CR, Salas⁃Alanis JC. The role of tumor necrosis factor⁃α in the pathogenesis of vitiligo[J]. Am J ClinDermatol, 2013, 14(5): 343⁃350. DOI: 10.1007/s40257⁃013⁃0039⁃3.
|
[27] |
Singh RK, Lee KM, Vujkovic⁃Cvijin I, et al. The role of IL⁃17 in vitiligo: a review[J]. Autoimmun Rev, 2016, 15(4):397⁃404.
|
[28] |
Wang S, Zhou M, Lin F, et al. Interferon⁃γ induces senescence in normal human melanocytes[J]. PLoS One, 2014, 9(3): e93232. DOI: 10.1371/journal.pone.0093232.
|
[29] |
Ning W, Wang S, Dong X, et al. Epigallocatechin⁃3⁃gallate (EGCG) suppresses the trafficking of lymphocytes to epidermal melanocytes via inhibition of JAK2: its implication for vitiligo treatment[J]. Biol Pharm Bull, 2015, 38(11): 1700⁃1706. DOI: 10.1248/bpb.b15⁃00331.
|
[30] |
Craiglow BG, King BA. Tofacitinib citrate for the treatment of vitiligo: a pathogenesis⁃directed therapy[J]. JAMA Dermatol, 2015, 151(10): 1110⁃1112. DOI: 10.1001/jamadermatol.2015.1520.
|
[31] |
Harris JE, Rashighi M, Nguyen NR et al. Rapid skin repig⁃mentation on oral ruxolitinib in a patient with coexistent vitiligo and alopecia areata (AA)[J]. J Am Acad Dermatol, 2016, 74(2): 370⁃371.
|